Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs Post author:Sam Post published:January 25, 2018 Post category:BioPharma The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace You Might Also Like Alnylam Announces Proposed Public Offering Of Common Stock May 23, 2017 Why AbbVie Could Join the M&A Mania Soon January 30, 2018 InDex Pharmaceuticals AB Appoints New CFO March 7, 2017
